NAD+ Nasal Spray: Does It Work for Focus?

An NAD+ nasal spray is sold on a simple promise: skip the gut, get the molecule closer to the brain, think more clearly. It is the format most telehealth clinics now lead with, and the one with the least evidence behind it. This page is the honest answer to the question people actually search — does an NAD+ nasal spray work for focus? — and the short version is that nobody has run the study that would tell you.

The short answer: nobody has tested it

There is no rigorous randomized trial of intranasal NAD+ for cognition, focus, or energy. Not a weak one — none. That is the single most important fact on this page, and it does not change with how confident a product page sounds.

It is worth being precise about what does exist for non-oral routes, because it gets overstated constantly. The only human parenteral-NAD+ data anyone can point to is a small pilot that characterized the pharmacokinetics of a 6-hour intravenous NAD+ infusion — it tracked how NAD+ and its metabolites moved through plasma and urine¹. That pilot measured no cognitive or focus outcomes at all. It was built to answer "where does the NAD+ go?", not "does it make you think better?" We take that route apart separately in NAD+ IV for Mental Clarity: Is It Worth It?. For the nasal route there is not even a pharmacokinetic study of that quality to point at.

It is a compounded drug, not an approved one

Before any evidence question there is a regulatory one, and most product pages skip it. A prescription NAD+ nasal spray is a compounded preparation — mixed to order by a compounding pharmacy on a clinician's prescription. In FDA's own words, "compounded drugs are not FDA-approved," which means the agency "does not verify the safety, effectiveness or quality of compounded drugs before they are marketed"².

That is not an accusation against any particular pharmacy. Compounding serves real medical needs, and a properly run 503A facility is a legitimate part of the system. It is a statement about what the label does and does not carry. FDA is equally explicit that when a compounded drug misses quality standards — contamination, or too much active ingredient — the consequence can be serious injury, and that compounded labels "may not include important information such as adequate directions" for safe use³. The review you are used to sitting behind a prescription is not sitting behind this one. That belongs on the page next to the price, including on our own top pick's row in the cognitive-energy ranking.

Absorption and efficacy are two separate claims

This is where nasal marketing does its real work. "Bypasses first-pass metabolism" and "reaches the brain" get run together with "improves focus" as though they were one sentence. They are three, and each needs its own evidence.

The route rationale is legitimate as a rationale. Nose-to-brain delivery is a genuine research field: the olfactory and trigeminal nerve pathways offer a direct, non-invasive way past the blood-brain barrier, and researchers pursue it precisely because that barrier blocks most therapeutic agents from the central nervous system⁴. That is why a nasal NAD+ product sounds plausible. It is not why it would work.

Because the field's verdict on itself is cautious. A 2026 review of olfactory versus respiratory targeting concludes that despite decades of research, nose-to-brain delivery still faces unresolved challenges — chiefly imprecise targeting of the olfactory epithelium, and no standardized models for establishing what is actually transported⁵. Only part of the nasal cavity is olfactory epithelium at all; the rest supports ordinary systemic absorption. "Intranasal" is a route being actively engineered for drugs designed around it, not a solved delivery mechanism a molecule inherits by being put in a spray bottle.

Then there is the molecule itself. Cells build NAD+ from precursors through salvage and de novo biosynthetic pathways rather than importing the finished cofactor wholesale — that biochemistry is the whole reason the supplement industry sells nicotinamide riboside and NMN instead of NAD+⁶. A 2023 review of NAD+ precursors in humans makes the same point from the other end: oral NR and NMN do raise NAD+, their effects are lower than the animal work predicted, and the field names delivery to target organs as an open problem still to be solved⁷. Open is the operative word. A spray does not close it by assertion.

Stack the claims and you can see how much has to be true at once: that a meaningful quantity of intranasal NAD+ is absorbed, that it reaches brain tissue rather than just plasma, and that raising NAD+ there changes how you think. None of the three has been demonstrated in a person. None has been refuted either — they simply have not been measured. Liposomal NAD+ and brain absorption walks the same wall from the oral side.

What the trials actually measured

The strongest thing the NAD+ field can show is that precursors raise the NAD+ biomarker, and it shows that well. Nicotinamide riboside is orally bioavailable in humans and raises blood NAD+⁸; an oral NMN formulation did the same in middle-aged and older adults⁹. Read the outcome those trials measured, though: blood NAD+. Not attention. Not fatigue. Not focus.

When a trial does measure thinking, the result stops being flattering. A randomized placebo-controlled trial of NR in older adults with mild cognitive impairment raised NAD+ and found no improvement in cognition versus placebo¹⁰. A 2025 randomized trial in long COVID — a population defined partly by brain fog — raised NAD+ roughly threefold and reported no significant benefit for cognition, fatigue, sleep, or mood¹¹. The marker moved; the experience did not.

That is the bar a nasal spray has to clear, and the direction the evidence runs matters. The route that has been tested for both delivery and cognition did not produce a cognitive benefit. The nasal route adds an unmeasured delivery step on top of an unproven effect; it is not a shortcut around the null result, it inherits it. The dose question runs into the same wall — see NAD+ dosing and cognitive benefits.

What it costs, format by format

Price is the one genuinely knowable thing about nasal NAD+, so it is worth being exact. Across the providers on our board, the spray is not systematically cheaper or dearer than the needle — the provider sets the number, not the route. CoreAge Rx charges a flat $93 a month for either format, the lowest clinician-supervised figure we track. HealthRX publishes $134 for the nasal spray against $161 for the injection. Shed's nasal headline is $144, though the final figure is confirmed only inside its patient portal. At the other end, MadeMed's nasal spray is $279 a month on a three-month plan and $269 on six — and MadeMed sells no single month at all, so its cheapest nasal rate is a $1,194 prepay.

The figures worth reading twice are the ones doing something other than what they appear to. Enhance MD advertises $169 a month for its injection; that is a twelve-month prepay, and the month-to-month rate is $199. Sprout Health's $199 is a first-month promotion against a $249 recurring rate. Hone Health quotes $165 for the medication and adds a $25 monthly membership on top. And three providers publish a starting figure while never stating a delivery route at all — Bodybuilding Health+ from $129, Care Bare Rx from $199, yourEra from $249 — so they cannot honestly be placed in a route comparison.

None of that is evidence, and a cheaper unproven spray is still an unproven spray. The table is here so that the price, at least, is the part you are not guessing at. What a month of NAD+ injections actually costs sets out the needle side in the same detail.

Tolerability: honestly, unstudied

Safety and efficacy are separate questions and deserve separate answers. On safety, oral precursors look reasonably benign: a randomized high-dose nicotinamide riboside trial found it generally safe and well tolerated¹², and a systematic review of randomized NAD+/NADH trials — ten studies, 489 participants, oral supplementation — found side effects that were common but not serious¹³.

Note what both of those cover. Oral. There is no published characterization of the tolerability of intranasal NAD+. Nasal mucosa is not gut, and the questions a real tolerability study would ask — irritation, burning, taste, what daily dosing and its excipients do to the nasal lining over months — have not been answered in print for this product. That is not a claim that it is dangerous. It is a statement that "NAD+ is well tolerated" is a sentence about capsules being quietly reused to sell a spray.

So, does an NAD+ nasal spray work for focus?

On current evidence: unproven, and unstudied rather than merely disappointing. There is no efficacy trial, no cognitive outcome from any parenteral route, no published human absorption data for the nasal route, no tolerability characterization, and no FDA review of the compounded product itself.

That is not the same as calling it a scam. NAD+ biology is real, nose-to-brain delivery is a serious research field, and a clinician-supervised program filled by a named 503A pharmacy is a different proposition from an anonymous storefront. But the question to hold a product to is not "does it raise NAD+?", and it certainly is not "does it bypass the gut?" It is: is there a human trial showing it improves the outcome I care about? For nasal NAD+, today, the answer is no — and being told that is worth more than being sold a result nobody has measured.

If focus is the actual problem, the higher-yield move is upstream. Does NAD+ Help Brain Fog? An Evidence Check covers the common, testable, treatable drivers — sleep, thyroid, iron, mood, medications — worth ruling in before any spray, and NAD+, Brain Fog & Focus: What the Evidence Shows is the full evidence review on the molecule. If you have read all of it and still want to try one, our cognitive-energy ranking prices every provider we track and states on every row that none of them has a trial.